LYRIC Mouse Monoclonal Antibody [C6-C10] (EM1901-60)

UNIPROT #

Q86UE4

PROTEIN NAME

LYRIC

SYNONYMS

3D3 antibody;3D3/LYRIC antibody;AEG 1 antibody;AEG-1 antibody;AEG1 antibody;Astrocyte elevated gene 1 antibody;Astrocyte elevated gene-1 protein antibody;LYRIC antibody;LYRIC/3D3 antibody;LYRIC_HUMAN antibody;Lysine rich CEACAM1 associated protein antibody;Lysine rich CEACAM1 co isolated protein antibody;Lysine-rich CEACAM1 co-isolated protein antibody;Metadherin antibody;Metastasis adhesion protein antibody;MTDH antibody;Protein LYRIC antibody

TISSUE SPECIFICITY

Widely expressed with highest levels in muscle-dominating organs such as skeletal muscle, heart, tongue and small intestine and in endocrine glands such as thyroid and adrenal gland. Overexpressed in various cancers including breast, brain, prostate, melanoma and glioblastoma multiforme.

SUBCELLULAR LOCATION

Nucleus membrane, nucleolus, endoplasmic reticulum membrane, tight junction, perinuclear region.

FUNCTION

Metadherin, also known as protein LYRIC or astrocyte elevated gene-1 protein (AEG-1) is a protein that in humans is encoded by the MTDH gene. MTDH (AEG-1) is involved in HIF-1alpha mediated angiogenesis. MTDH also interacts with SND1 and involved in RNA-induced silencing complex (RISC) and plays very important role in RISC and miRNA functions. MTDH has been shown to interact with spliceosome proteins in the cell nucleus and regulate the process of alternative splicing. MTDH induces an oncogene called Late SV40 factor (LSF/TFCP2) which is involved in thymidylate synthase (TS) induction and DNA biosynthesis synthesis. Late SV40 factor (LSF/TFCP2) enhances angiogenesis by transcriptionally up-regulating matrix metalloproteinase-9 (MMP9). MTDH acts as an oncogene in melanoma, malignant glioma, breast cancer and hepatocellular carcinoma. It is highly expressed in these cancers and helps in progression and development of these cancers. It is induced by c-Myc oncogene and plays very important role in anchorage independent growth of cancer cells. Elevated expression of the metastasis gene metadherin (MTDH), which is overexpressed in more than 40% of breast cancers, is associated with poor clinical outcomes.